AKBA Akebia Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AKBA

Price (delayed)

$1.1

Market cap

$204.52M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.3

Enterprise value

$225.28M

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is ...

Highlights
The company's gross margin has surged by 124% YoY and by 3% QoQ
Akebia Therapeutics's EPS has soared by 81% YoY and by 41% from the previous quarter
AKBA's gross profit has surged by 172% year-on-year but it is down by 4.7% since the previous quarter
Akebia Therapeutics's revenue has increased by 22% YoY but it has decreased by 7% QoQ
The equity has dropped by 155% year-on-year
The company's quick ratio fell by 13% QoQ and by 4.3% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://akebia.com
Peers: AMGN JNJ NKTR ENZN

Key stats

What are the main financial stats of AKBA
Market
Shares outstanding
185.93M
Market cap
$204.52M
Enterprise value
$225.28M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.83
Earnings
Revenue
$271.03M
EBIT
-$44.17M
EBITDA
-$8.93M
Free cash flow
-$69.07M
Per share
EPS
-$0.3
Free cash flow per share
-$0.37
Book value per share
-$0.08
Revenue per share
$1.47
TBVPS
$0.86
Balance sheet
Total assets
$276.86M
Total liabilities
$291.21M
Debt
$77.71M
Equity
-$14.35M
Working capital
$37.78M
Liquidity
Debt to equity
-5.41
Current ratio
1.46
Quick ratio
0.9
Net debt/EBITDA
-2.32
Margins
EBITDA margin
-3.3%
Gross margin
73.1%
Net margin
-20.8%
Operating margin
-16.8%
Efficiency
Return on assets
-14.2%
Return on equity
-316.9%
Return on invested capital
-44.9%
Return on capital employed
-22.8%
Return on sales
-16.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AKBA stock price

How has the Akebia Therapeutics stock price performed over time
Intraday
0.92%
1 week
-2.65%
1 month
24.42%
1 year
205.98%
YTD
90.64%
QTD
96.29%

Financial performance

How have Akebia Therapeutics's revenue and profit performed over time
Revenue
$271.03M
Gross profit
$198.09M
Operating income
-$45.56M
Net income
-$56.36M
Gross margin
73.1%
Net margin
-20.8%
AKBA's gross profit has surged by 172% year-on-year but it is down by 4.7% since the previous quarter
The company's gross margin has surged by 124% YoY and by 3% QoQ
The operating margin has soared by 86% YoY and by 38% from the previous quarter
AKBA's net margin has surged by 83% year-on-year and by 34% since the previous quarter

Growth

What is Akebia Therapeutics's growth rate over time

Valuation

What is Akebia Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.83
Akebia Therapeutics's EPS has soared by 81% YoY and by 41% from the previous quarter
The equity has dropped by 155% year-on-year
The price to sales (P/S) is 150% more than the last 4 quarters average of 0.3 but 61% less than the 5-year quarterly average of 1.9
Akebia Therapeutics's revenue has increased by 22% YoY but it has decreased by 7% QoQ

Efficiency

How efficient is Akebia Therapeutics business performance
Akebia Therapeutics's ROS has soared by 86% YoY and by 38% from the previous quarter
The return on invested capital has surged by 80% year-on-year and by 44% since the previous quarter
The ROA has soared by 71% YoY and by 29% from the previous quarter
Akebia Therapeutics's return on equity has decreased by 19% YoY but it has increased by 4.5% QoQ

Dividends

What is AKBA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AKBA.

Financial health

How did Akebia Therapeutics financials performed over time
AKBA's total assets is 4.9% smaller than its total liabilities
AKBA's total assets is down by 48% year-on-year and by 21% since the previous quarter
The total liabilities has contracted by 43% YoY and by 15% from the previous quarter
The equity has dropped by 155% year-on-year
The debt to equity has dropped by 153% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.